8-K: Delcath Systems Expands Board, Addresses Nasdaq Compliance Issue

Delcath Systems appointed a new director, Bridget Martell, and is working to regain compliance with Nasdaq listing rules regarding audit committee composition.

Summary

• Delcath Systems held its 2024 annual meeting on May 23, 2024, where stockholders approved an increase of 2,000,000 shares to the 2020 Omnibus Equity Incentive Plan.
• Roger Stoll retired from the Board and Audit Committee, effective May 23, 2024, leaving the Audit Committee with only two qualified directors.
• Nasdaq notified Delcath on May 29, 2024, that the company was not in compliance with listing rule 5605(c)(2), which requires at least three qualified directors on the Audit Committee.
• Delcath has a cure period until the earlier of the next annual meeting or May 23, 2025, to regain compliance.
• Bridget Martell, M.A., M.D., was appointed as a Class III Director on the Board, commencing May 23, 2024, with her term expiring at the 2027 Annual Meeting.
• At the annual meeting, 65.94% of outstanding shares were present or represented by proxy.
• Stockholders elected Steven Salamon as a Class III director, approved the amendment to the 2020 EIP, ratified Marcum, LLP as the independent auditor, and approved a non-binding advisory vote on executive compensation.

Sentiment

Score: 5

Explanation: The document contains both positive and negative elements. The appointment of a new director is positive, but the Nasdaq non-compliance is a concern. Overall, the sentiment is neutral.

Positives

• The company successfully increased the number of shares available under the 2020 Omnibus Equity Incentive Plan by 2,000,000.
• A new director, Bridget Martell, with extensive experience in biotechnology and oncology, has been appointed to the board.
• The company has a cure period to regain compliance with Nasdaq listing rules.

Negatives

• The retirement of Roger Stoll resulted in the company's non-compliance with Nasdaq listing rule 5605(c)(2).
• The Audit Committee currently has only two qualified directors, which is below the required minimum of three.

Risks

• Failure to appoint a third qualified director to the Audit Committee by the end of the cure period could result in further action by Nasdaq.
• The company needs to ensure that the new director is qualified to serve on the Audit Committee to regain compliance.

Future Outlook

The company intends to fill the vacancy on the Audit Committee as expeditiously as possible and expects to regain compliance with Nasdaq listing rules by the end of the cure period.

Management Comments

• John Sylvester, Chairman of the Delcath Board of Directors, stated that Dr. Martell's experience will be a great asset to Delcath.
• Dr. Martell said she is excited to be joining Delcath's Board at this crucial time and looks forward to supporting the team.

Industry Context

The appointment of a director with extensive experience in biotechnology and oncology aligns with Delcath's focus on developing treatments for liver cancers. The company's need to address Nasdaq compliance issues is a common challenge for publicly traded companies.

Comparison to Industry Standards

• Many publicly traded companies, especially in the biotech sector, face challenges in maintaining compliance with listing requirements.
• The need to have a fully qualified audit committee is a standard requirement for companies listed on major exchanges like Nasdaq.
• Delcath's situation is not unique, and many companies have had to address similar compliance issues.
• The appointment of a director with relevant industry experience is a common practice to strengthen the board and provide valuable insights.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may be concerned about the company's non-compliance with Nasdaq listing rules.
• The appointment of a new director may be viewed positively by investors.
• Employees may be affected by any changes in the company's governance structure.

Next Steps

• Delcath will need to appoint a third qualified director to the Audit Committee.
• The company will need to communicate with Nasdaq to ensure compliance is regained within the cure period.

Key Dates

Keywords

Delcath Systems, Nasdaq, Audit Committee, Board of Directors, Equity Incentive Plan, Director Appointment, Listing Rule, Compliance, Stockholders Meeting, Corporate Governance